Biolase

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Marc2pk
Forum gebruiker
Forum gebruiker
Berichten: 106
Lid geworden op: 07 Nov 2012 16:23
waarderingen: 18
Contact:

Re: Biolase

Berichtdoor Marc2pk » 18 Aug 2013 22:49

MILJAAR,

Net terug uit de Ardennen.
Zo een val niet verwacht, puur paniek.
FDA goedkeuringen, pattenten, nieuwe managers, etc....
Eventjes broek optrekken, maar ik blijf nog steeds geloven in Biolase.
Naïef?


Lodewijk
Forum verkenner
Forum verkenner
Berichten: 40
Lid geworden op: 10 Jan 2013 11:19
waarderingen: 1
Contact:

Re: Biolase

Berichtdoor Lodewijk » 21 Aug 2013 15:54

Nog meer negatief nieuws !
Ik hoop dat iedereen even uitgestapt is.


Overview

Management of Biolase (BIOL) has repeatedly tried to mask bad news through the use of euphemistic and creative wording in disclosures and press releases. Biolase has also tried to create a false boogeyman of "illegal naked short sellers" even though there is demonstrably no naked short selling going on with the stock. I will demonstrate this clearly below. The continued weakness in the share price is not due to short selling. Instead it is the result of a complete loss of confidence by long investors who are not being fooled by the continued shenanigans of management.

The continued driver of the share price will be Biolase's liquidity position along with the upcoming stock offering at a discount.

There is nothing illegal or immoral about shorting the stock of a company. Companies who deliver on performance will see their share prices rise. Those which do not will see their share prices fall.

Shorts have done far less selling than longs

I recently wrote two articles on Biolase. At the time of both articles, the share price was around $1.80 and had already plunged by 50% following a moderate earnings miss announced on August 7th after the close. I did not cause this plunge. Instead I was writing about it after it already happened.

The moderate earnings miss was certainly not justification for the steep plunge. Instead it was solvency concerns and the expectation of an equity offering at a discount. As soon as earnings were announced, the stock fell by more than 20%.

The share price continued its steep dive nearly every day and within a week was down by more than 50%. The falling share price triggered a short sale restriction, such that short sellers could only sell upon an uptick. This means that one could only sell short when a buyer chose to lift the price and buy at the ask. Short sellers could not hit the bid.

This means that short selling would not have been able to put any pressure on the share price whatsoever. Instead, it was a rush for the exits by long holders of Biolase stock.

Lodewijk
Forum verkenner
Forum verkenner
Berichten: 40
Lid geworden op: 10 Jan 2013 11:19
waarderingen: 1
Contact:

Re: Biolase

Berichtdoor Lodewijk » 29 Aug 2013 07:43

Hebben wij hier nog grootaandeelhouders in Biolase ? :?

ALERT: The Rosen Law Firm Announces Class Action Against Biolase, Inc. -- BIOL

NEW YORK, Aug. 28, 2013 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. that a class action lawsuit has been filed on behalf of all purchasers of the securities of Biolase, Inc. (Nasdaq:BIOL) between November 5, 2012 and August 7, 2013.

To join the Biolase class action, visit the firm's website at http://www.rosenlegal.com" onclick="window.open(this.href);return false;, or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free, at 866-767-3653; you may also email at pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was facing near term solvency issues; (ii) the Company faced severe liquidity problems; (iii) the Company's sales were not as strong as reported; and (iv) as a result of the foregoing, the Company's financial statements were false and misleading at all relevant times. The lawsuit claims that when these adverse facts entered the market, the value of Biolase shares fell, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than October 22, 2013. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Stefan
Forum actieveling
Forum actieveling
Berichten: 479
Lid geworden op: 18 Dec 2012 18:52
waarderingen: 58
Contact:

Re: Biolase

Berichtdoor Stefan » 08 Nov 2013 11:57

Zijn er nog mensen die aandelen hebben van Biolase? Ik heb het gevoel dat de negativiteit rond dit aandeel rustig aan het verdwijnen is. Volgende week ook cijfers.

Wat zijn de verwachtingen? Ik ben aan het twijfelen om in te stappen.
Biolase ($1.91)
Senomyx ($1.21)
Thrombogenics (€3,32)

Marc2pk
Forum gebruiker
Forum gebruiker
Berichten: 106
Lid geworden op: 07 Nov 2012 16:23
waarderingen: 18
Contact:

Re: Biolase

Berichtdoor Marc2pk » 08 Nov 2013 13:12

Stefan,

Heb mijn aandelen van Biolase altijd bijgehouden.
Geen idee over de resultaten. Hopelijk positief.
Momenteel zit ik met verlies, gekocht aan 3,4$ en
bijgekocht aan 2,8$.
Toch blijf ik mijn vertrouwen in Biolase behouden.
De vooruitzichten zijn in ieder geval goed, één nadeel
zijn de cashproblemen.
Biolase staat spotgoedkoop, paar jaar geleden stonden ze
op 20$, met slechtere papieren.
Pas op Stefan dit is geen advies om te kopen!
Dit moet je zelf beslissen. In ieder geval is dit een LT-aandeel.
Dividend word steeds uitgekeerd in aandelen.
Groetjes

Stefan
Forum actieveling
Forum actieveling
Berichten: 479
Lid geworden op: 18 Dec 2012 18:52
waarderingen: 58
Contact:

Re: Biolase

Berichtdoor Stefan » 08 Nov 2013 14:13

Marc2pk schreef:Stefan,

Heb mijn aandelen van Biolase altijd bijgehouden.
Geen idee over de resultaten. Hopelijk positief.
Momenteel zit ik met verlies, gekocht aan 3,4$ en
bijgekocht aan 2,8$.
Toch blijf ik mijn vertrouwen in Biolase behouden.
De vooruitzichten zijn in ieder geval goed, één nadeel
zijn de cashproblemen.
Biolase staat spotgoedkoop, paar jaar geleden stonden ze
op 20$, met slechtere papieren.
Pas op Stefan dit is geen advies om te kopen!
Dit moet je zelf beslissen. In ieder geval is dit een LT-aandeel.
Dividend word steeds uitgekeerd in aandelen.
Groetjes


Bedankt voor de uitleg Marc!
Ik zie overal koersdoelen staan van $3 tot $7, vooruitzichten zijn volgens mij dan ook goed.
Vandaag zal ik dus hoogstwaarschijnlijk instappen.
Biolase ($1.91)
Senomyx ($1.21)
Thrombogenics (€3,32)

Opportunity
Forum actieveling
Forum actieveling
Berichten: 354
Lid geworden op: 18 Okt 2012 14:27
waarderingen: 33
Contact:

Re: Biolase

Berichtdoor Opportunity » 08 Nov 2013 15:14

Ik heb deze ook een tijdje gehad maar ben er uitgestapt. De negatieve buzz rond het bedrijf blijft hier en daar toch aanhouden hoor.. Het blijft verdacht dat het bedrijf om de haverklap persberichten de wereld instuurt, het lijkt echt een 'goed nieuws show' ipv een mededeling.

Toch voorzichtig zijn vind ik.. Persoonlijk twijfel ik te veel aan het bedrijf om nog iets zwaar te riskeren.

Stefan
Forum actieveling
Forum actieveling
Berichten: 479
Lid geworden op: 18 Dec 2012 18:52
waarderingen: 58
Contact:

Re: Biolase

Berichtdoor Stefan » 12 Nov 2013 15:50

Biolase krijgt er van langs momenteel. Ik heb vandaag mijn eerste pakket aangekocht aan $1.62 en zal de komende dagen een 2de pakket aankopen. De cijfers waren in mijn ogen zeker niet slecht en tov vorig jaar is er toch een hele verbetering gekomen.
Biolase ($1.91)
Senomyx ($1.21)
Thrombogenics (€3,32)

Stefan
Forum actieveling
Forum actieveling
Berichten: 479
Lid geworden op: 18 Dec 2012 18:52
waarderingen: 58
Contact:

Re: Biolase

Berichtdoor Stefan » 12 Nov 2013 17:00

Financial Highlights for the Nine Months and Third Quarter ended September 30, 2013:
•Net revenue of $41.2 million for the nine months ended September 30, 2013, an 8% increase over net revenues of $38.3 million for the same prior year period.
•Net revenue of $12.3 million for Q3 2013, a 10% decrease as compared to net revenues of $13.8 million for Q3 2012.
•Non-GAAP net loss for Q3 2013 of $3.2 million, or a loss of $0.10 per share, as compared to non-GAAP net income of $96,000, or income of $0.00 per share, for Q3 2012.
•Increased reserve for excess and obsolete inventory by $1 million during Q3 2013; one time charge had direct impact to cost of sales and gross margin for the quarter and nine months ended September 30, 2013.
•Net revenue from the sale of core laser systems increased approximately $90,000, or 0.3%, for the nine months ended September 30, 2013, as compared to the prior year period; decreased approximately $2.0 million, or 20%, for Q3 2013 as compared to Q3 2012.
•Net revenue from the sale of digital imaging systems and CAD/CAM intraoral scanners increased approximately $1.6 million, or 94%, for the nine months ended September 30, 2013, as compared to the prior year period.

Operating Highlights of the 2013 Third Quarter:
•Sold 2,688,172 shares of common stock in a registered direct public offering to a single investor, Camber Capital Management, LLC ("Camber"). The offering price of $1.86 per share, a price equal to the closing price on September 23, 2013, resulted in gross proceeds of $5 million, before deducting placement agent commissions and offering expenses of approximately $408,000.
•Entered into a strategic agreement with Valam Corporation to develop, market, and sell office-based laser systems to Ear, Nose, and Throat (or "ENT") doctors; BIOLASE's EPIC 10 soft-tissue laser is cleared by the FDA for use in ENT surgical procedures.
•An informational news segment discussing the use of BIOLASE's WaterLase in dental procedures aired on CNBC on Saturday, August 17, 2013, and will be aired on upcoming broadcasts of the Fox Business Network and Bloomberg International Network in the coming months.
•Declared a one-half percent stock dividend payable on September 13, 2013, to stockholders of record as of August 30, 2013.

Other Highlights of the 2013 Third Quarter:
•Granted several new patents:
◦In the U.S. for mitigating the effects of presbyopia using infrared lasers; significantly expands on BIOLASE's previously issued U.S. Patent No. 7,665,467 regarding methods and devices for treating presbyopia.
◦In the U.S. and Japan for delivering sterile water; significantly expands on BIOLASE's fluid conditioning system technology which is already covered in several U.S. and international patents.
◦In the U.S. for finger switch actuation of handheld medical instrumentation; an innovative new patent that addresses the need for improved efficiency and space accommodation in surgical operating rooms.

•WaterLase technology was featured in 18 new peer-reviewed journal articles published in the English language during the 2013 third quarter. These articles concluded, among other things, that lasers improve the removal of debris in root canals, WaterLase technology leads to a high bactericidal effect with a significant reduction in operating times, WaterLase technology has a shallower learning curve for dentists, and WaterLase assisted endodontic treatment using radial firing tips lead to less adverse effects.

Highlights Subsequent to the 2013 Third Quarter:
•Entered letter of commitment with Auris Surgical Robotics, Inc. ("Auris"), the developer of a robotic microsurgical system designed specifically for ophthalmic surgery, to develop a new product for ophthalmologists; the product is planned to feature BIOLASE's patented WaterLase YSGG all-tissue atraumatic cutting technology mounted on a unique robotic operating system manufactured by Auris.
•Issued a new patent in the U.S. for treating eye conditions with low-level light therapy; significantly expands on a previously issued U.S. Patent regarding methods and devices for treating presbyopia.
•Named industry veteran Brian Jaffe as Vice President, North American Sales and Marketing. Mr. Jaffe comes to BIOLASE from Millennium Dental Technologies, where he held the position of Vice President of Global Sales.
•Amended our two revolving credit agreements with Comerica Bank to waive non-compliance with our earnings before income tax, depreciation, and amortization ("EBITDA") covenant at September 30, 2013.
Biolase ($1.91)
Senomyx ($1.21)
Thrombogenics (€3,32)

Opportunity
Forum actieveling
Forum actieveling
Berichten: 354
Lid geworden op: 18 Okt 2012 14:27
waarderingen: 33
Contact:

Re: Biolase

Berichtdoor Opportunity » 15 Nov 2013 10:44

Heb hier na de val ook een kleine 'dead cat bounce' play geinitieerd. Momenteel al mooi groen met zeer korte stop die ik dagelijks herevalueer. Ik denk dat hier nog een 'gap fill' aan de orde is. Mijn verkoopdoel: 2 dollar.